FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004950002> ?p ?o ?g. }

• W2004950002 endingPage "2076" @default.
• W2004950002 startingPage "2071" @default.
• W2004950002 abstract "We report the results of a randomised phase II trial of docetaxel tested as a single agent in patients with recurrent head and neck cancer using methotrexate as a control arm to validate the results. Eligibility criteria included: histologically-confirmed squamous cell carcinoma, measurable disease, adequate haematological, renal and hepatic functions, no prior chemotherapy for recurrent cancer, signed informed consent. 40 mg/m2 methotrexate was given as a short weekly bolus i.v. injection, and 40 mg/m2 docetaxel was administered as a one hour weekly infusion. A total of 57 patients were randomised based on a ratio of 2/1:37 and 20 patients received docetaxel and methotrexate, respectively. Patient characteristics included 49 males and 8 females; the median age was 59 years (range: 43–82 years). Twenty-eight patients had a local-regional relapse and 29 had distant metastasis, the median disease-free interval was 7.9 months (range: 0–165 months). For patients treated with docetaxel, the following grade 3–4 toxicities occurred: neutropenia (12.5%) with febrile neutropenia in one patient (1%), anaemia (19%) mucositis (9%) and ungueal toxicity (9%). In the methotrexate arm, the grade 3–4 toxicities were: anaemia (15%) and mucositis (5%). The response rate was significantly higher in the docetaxel arm with 27% (95% confidence interval (CI): 21.7–32.3%) of objective responses versus 15% (95% CI: 11.2–18.8%) in the methotrexate arm. Overall survival and time to progression were super-imposable between the docetaxel and methotrexate treatments. Docetaxel given as a weekly infusion has a high activity in patients with head and neck cancer. A phase III trial is needed to test if this translates into a survival benefit for docetaxel use." @default.
• W2004950002 created "2016-06-24" @default.
• W2004950002 creator A5004823659 @default.
• W2004950002 creator A5006416930 @default.
• W2004950002 creator A5026883860 @default.
• W2004950002 creator A5035753830 @default.
• W2004950002 creator A5040549888 @default.
• W2004950002 creator A5042202815 @default.
• W2004950002 creator A5044903892 @default.
• W2004950002 creator A5047134107 @default.
• W2004950002 creator A5066162032 @default.
• W2004950002 creator A5069087546 @default.
• W2004950002 creator A5085647218 @default.
• W2004950002 creator A5089019258 @default.
• W2004950002 date "2004-09-01" @default.
• W2004950002 modified "2023-10-02" @default.
• W2004950002 title "Results of a randomised phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer" @default.
• W2004950002 cites W1765857451 @default.
• W2004950002 cites W1891799419 @default.
• W2004950002 cites W1920828316 @default.
• W2004950002 cites W1952422131 @default.
• W2004950002 cites W1992461309 @default.
• W2004950002 cites W1993012255 @default.
• W2004950002 cites W2029409133 @default.
• W2004950002 cites W2044450235 @default.
• W2004950002 cites W2127716356 @default.
• W2004950002 cites W2131657493 @default.
• W2004950002 cites W2290932069 @default.
• W2004950002 cites W2406213538 @default.
• W2004950002 cites W4206795917 @default.
• W2004950002 doi "https://doi.org/10.1016/j.ejca.2004.05.019" @default.
• W2004950002 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15341981" @default.
• W2004950002 hasPublicationYear "2004" @default.
• W2004950002 type Work @default.
• W2004950002 sameAs 2004950002 @default.
• W2004950002 citedByCount "100" @default.
• W2004950002 countsByYear W20049500022012 @default.
• W2004950002 countsByYear W20049500022013 @default.
• W2004950002 countsByYear W20049500022014 @default.
• W2004950002 countsByYear W20049500022015 @default.
• W2004950002 countsByYear W20049500022016 @default.
• W2004950002 countsByYear W20049500022017 @default.
• W2004950002 countsByYear W20049500022018 @default.
• W2004950002 countsByYear W20049500022019 @default.
• W2004950002 countsByYear W20049500022020 @default.
• W2004950002 countsByYear W20049500022021 @default.
• W2004950002 countsByYear W20049500022022 @default.
• W2004950002 countsByYear W20049500022023 @default.
• W2004950002 crossrefType "journal-article" @default.
• W2004950002 hasAuthorship W2004950002A5004823659 @default.
• W2004950002 hasAuthorship W2004950002A5006416930 @default.
• W2004950002 hasAuthorship W2004950002A5026883860 @default.
• W2004950002 hasAuthorship W2004950002A5035753830 @default.
• W2004950002 hasAuthorship W2004950002A5040549888 @default.
• W2004950002 hasAuthorship W2004950002A5042202815 @default.
• W2004950002 hasAuthorship W2004950002A5044903892 @default.
• W2004950002 hasAuthorship W2004950002A5047134107 @default.
• W2004950002 hasAuthorship W2004950002A5066162032 @default.
• W2004950002 hasAuthorship W2004950002A5069087546 @default.
• W2004950002 hasAuthorship W2004950002A5085647218 @default.
• W2004950002 hasAuthorship W2004950002A5089019258 @default.
• W2004950002 hasConcept C121608353 @default.
• W2004950002 hasConcept C126322002 @default.
• W2004950002 hasConcept C141071460 @default.
• W2004950002 hasConcept C143998085 @default.
• W2004950002 hasConcept C2776530083 @default.
• W2004950002 hasConcept C2776694085 @default.
• W2004950002 hasConcept C2777063308 @default.
• W2004950002 hasConcept C2778496288 @default.
• W2004950002 hasConcept C2778850193 @default.
• W2004950002 hasConcept C2781059491 @default.
• W2004950002 hasConcept C2781190966 @default.
• W2004950002 hasConcept C71924100 @default.
• W2004950002 hasConcept C90924648 @default.
• W2004950002 hasConceptScore W2004950002C121608353 @default.
• W2004950002 hasConceptScore W2004950002C126322002 @default.
• W2004950002 hasConceptScore W2004950002C141071460 @default.
• W2004950002 hasConceptScore W2004950002C143998085 @default.
• W2004950002 hasConceptScore W2004950002C2776530083 @default.
• W2004950002 hasConceptScore W2004950002C2776694085 @default.
• W2004950002 hasConceptScore W2004950002C2777063308 @default.
• W2004950002 hasConceptScore W2004950002C2778496288 @default.
• W2004950002 hasConceptScore W2004950002C2778850193 @default.
• W2004950002 hasConceptScore W2004950002C2781059491 @default.
• W2004950002 hasConceptScore W2004950002C2781190966 @default.
• W2004950002 hasConceptScore W2004950002C71924100 @default.
• W2004950002 hasConceptScore W2004950002C90924648 @default.
• W2004950002 hasIssue "14" @default.
• W2004950002 hasLocation W20049500021 @default.
• W2004950002 hasLocation W20049500022 @default.
• W2004950002 hasOpenAccess W2004950002 @default.
• W2004950002 hasPrimaryLocation W20049500021 @default.
• W2004950002 hasRelatedWork W1606129292 @default.
• W2004950002 hasRelatedWork W2005735799 @default.
• W2004950002 hasRelatedWork W2076236941 @default.
• W2004950002 hasRelatedWork W2084246274 @default.
• W2004950002 hasRelatedWork W2104253325 @default.
• W2004950002 hasRelatedWork W2106964779 @default.

• next